Vanguard Group
KRTX

Vanguard Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Vanguard Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,224,786
Closed -$1.02B – 4503
2023
Q4 		$1.02B Buy
3,224,786
+21,201
+0.7% +$4.12M 0.02% 618
2023
Q3 		$542M Buy
3,203,585
+105,686
+3% +$19.9M 0.01% 859
2023
Q2 		$672M Buy
3,097,899
+78,353
+3% +$16.8M 0.02% 758
2023
Q1 		$548M Buy
3,019,546
+266,003
+10% +$50.9M 0.01% 848
2022
Q4 		$541M Buy
2,753,543
+131,958
+5% +$28.3M 0.01% 835
2022
Q3 		$590M Buy
2,621,585
+448,871
+21% +$90.9M 0.02% 740
2022
Q2 		$275M Buy
2,172,714
+51,562
+2% +$5.93M 0.01% 1235
2022
Q1 		$269M Buy
2,121,152
+36,816
+2% +$4.15M 0.01% 1354
2021
Q4 		$273M Buy
2,084,336
+18,945
+0.9% +$2.45M 0.01% 1411
2021
Q3 		$253M Buy
2,065,391
+49,641
+2% +$5.73M 0.01% 1452
2021
Q2 		$230M Buy
2,015,750
+106,547
+6% +$12.5M 0.01% 1548
2021
Q1 		$230M Buy
1,909,203
+690,602
+57% +$78.2M 0.01% 1514
2020
Q4 		$124M Buy
1,218,601
+25,847
+2% +$2.39M ﹤0.01% 1729
2020
Q3 		$92.2M Buy
1,192,754
+102,202
+9% +$8.71M ﹤0.01% 1725
2020
Q2 		$122M Buy
1,090,552
+587,085
+117% +$51M ﹤0.01% 1571
2020
Q1 		$36.3M Buy
503,467
+73,513
+17% +$6.29M ﹤0.01% 2012
2019
Q4 		$32.4M Buy
429,954
+208,074
+94% +$9.11M ﹤0.01% 2310
2019
Q3 		$3.62M Buy
221,880
+157,268
+243% +$3.06M ﹤0.01% 3253
2019
Q2 		$1.29M Buy
+64,612
New +$1.29M ﹤0.01% 3596

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Vanguard Group's KRTX Position: Q1 2024 in Review

Vanguard Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 3,224,786 shares — an estimated $1.02B sold.

Vanguard Group first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $1.02B in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Vanguard Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 3,224,786 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.02B.
  • Vanguard Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • Vanguard Group's Karuna Therapeutics, Inc. Common Stock position peaked at $1.02B in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.